NeuroD1: A Potential Drug Target for Neuropsychiatric Disorders

Target Name: NEUROD1

NCBI ID: G4760

NEUROD1

NeuroD1: A Potential Drug Target for Neuropsychiatric Disorders

NeuroD1, also known as D1, is a protein that is expressed in the brain and is involved in the development and maintenance of neuronal excitability. It is a key regulator of the electrical activity of neurons and is thought to play a crucial role in the function of the brain.

Recent studies have identified NeuroD1 as a potential drug target for a variety of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. This is because the dysfunction of NeuroD1 has been implicated in the pathophysiology of these disorders, and because neurotoxins that inhibit NeuroD1 have been shown to exacerbate the symptoms of these disorders.

One of the key mechanisms by which NeuroD1 contributes to the pathophysiology of these disorders is by modulating the levels of neurotransmitters, such as dopamine and synaptophysin, in the brain. These neurotransmitters are responsible for transmitting signals between neurons and are critical for the proper functioning of the brain. The dysfunction of NeuroD1 has been implicated in the misregulation of neurotransmitter levels, which can lead to the symptoms of these disorders.

In addition to its role in modulating neurotransmitter levels, NeuroD1 is also thought to play a key role in the development and maintenance of neuronal excitability. Neurons are specialized cells that are responsible for transmitting signals in the brain, and their ability to do so is dependent on the electrical activity of the cell. The dysfunction of NeuroD1 has been implicated in the misregulation of neuronal excitability, which can lead to the symptoms of neuropsychiatric disorders.

One of the key consequences of the dysfunction of NeuroD1 is the misregulation of neurotransmitter levels. This can lead to the symptoms of neuropsychiatric disorders, such as anxiety, depression, and psychosis. For example, studies have shown that mice that have been genetically modified to lack for NeuroD1 have exhibited symptoms of anxiety and depression, while those that have been overexpressed have exhibited hyperactivity.

In addition to its role in modulating neurotransmitter levels and contributing to the misregulation of neuronal excitability, NeuroD1 is also thought to play a key role in the development and maintenance of neuronal diversity. Neurons are highly diverse cells that have a variety of different types and functions, and the dysfunction of NeuroD1 has been implicated in the loss of neuronal diversity.

The misregulation of NeuroD1 has been implicated in a variety of neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. These disorders are characterized by the dysfunction of neural networks in the brain, which can lead to the misfunctioning of specific brain regions. For example, studies have shown that the dysfunction of NeuroD1 has been implicated in the misregulation of dopamine levels in the brain, which can contribute to the symptoms of Alzheimer's disease.

In addition to its role in the development and maintenance of neuronal diversity, NeuroD1 is also thought to play a key role in the regulation of synaptic plasticity, which is the ability of the brain to learn and adapt over time. The dysfunction of NeuroD1 has been implicated in the misregulation of synaptic plasticity, which can lead to the inability to learn and adapt, a key symptom of neuropsychiatric disorders.

In conclusion, NeuroD1 is a protein that is involved in the development and maintenance of neuronal excitability and is thought to play a crucial role in the function of the brain. Its dysfunction has been implicated in the pathophysiology of a variety of neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. Therefore, NeuroD1 is a promising target for drug development

Protein Name: Neuronal Differentiation 1

Functions: Acts as a transcriptional activator: mediates transcriptional activation by binding to E box-containing promoter consensus core sequences 5'-CANNTG-3'. Associates with the p300/CBP transcription coactivator complex to stimulate transcription of the secretin gene as well as the gene encoding the cyclin-dependent kinase inhibitor CDKN1A. Contributes to the regulation of several cell differentiation pathways, like those that promote the formation of early retinal ganglion cells, inner ear sensory neurons, granule cells forming either the cerebellum or the dentate gyrus cell layer of the hippocampus, endocrine islet cells of the pancreas and enteroendocrine cells of the small intestine. Together with PAX6 or SIX3, is required for the regulation of amacrine cell fate specification. Also required for dendrite morphogenesis and maintenance in the cerebellar cortex. Associates with chromatin to enhancer regulatory elements in genes encoding key transcriptional regulators of neurogenesis (By similarity)

The "NEUROD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NEUROD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets